RA Capital Management Details $40M Purchase of Bicara Therapeutics Stock and Warrants
BCAX has more than doubled off its 52-week low of $7.8.
Summary
RA Capital Management, a 10% owner and director, reported a significant $40 million open market purchase of Bicara Therapeutics common stock and pre-funded warrants, detailing its participation in the recent public offering.
Key Events · Ownership and Investor Activity · BCAX
-
Major Insider Purchase
RA Capital Management, a 10% owner and director, acquired $39,999,780 worth of Bicara Therapeutics shares and pre-funded warrants.
-
Participation in Public Offering
The purchase was executed on February 26, 2026, aligning with the closing date of Bicara Therapeutics' recent public offering, which raised $161.8 million.
-
Significant Stake
The transaction represents a substantial investment, reinforcing RA Capital's position as a key shareholder and demonstrating confidence in the company's outlook.
Analysis · BCAX · Life Sciences
This Form 4 provides the specific transaction details for the $40 million investment by RA Capital Management, a major institutional investor with board representation, into Bicara Therapeutics. This purchase, which includes both common stock and pre-funded warrants, was part of the company's recently closed public offering. The substantial investment, representing over 4% of the company's market capitalization, signals strong confidence from a key insider in Bicara's future prospects and its ability to fund drug development. This filing complements the concurrent Schedule 13D/A and prior offering disclosures by providing granular transaction data.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BCAX was trading at $18.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $963.6M. The 52-week trading range was $7.80 to $19.71. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.